Search Results - "HANF, RéMY"

Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis by Staels, Bart, Rubenstrunk, Anne, Noel, Benoit, Rigou, Géraldine, Delataille, Philippe, Millatt, Lesley J., Baron, Morgane, Lucas, Anthony, Tailleux, Anne, Hum, Dean W., Ratziu, Vlad, Cariou, Bertrand, Hanf, Rémy

“…Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and…”
Get full text

Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects by CARIOU, Bertrand, HANF, Rémy, LAMBERT-PORCHERON, Stéphanie, ZAÏR, Yassine, SAUVINET, Valérie, NOËL, Benoit, FLET, Laurent, VIDAL, Hubert, STAELS, Bart, LAVILLE, Martine

“…The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome…”
Get full text

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study by Harrison, Stephen A, Ratziu, Vlad, Boursier, Jérôme, Francque, Sven, Bedossa, Pierre, Majd, Zouher, Cordonnier, Geneviève, Sudrik, Fouad Ben, Darteil, Raphael, Liebe, Roman, Magnanensi, Jérémy, Hajji, Yacine, Brozek, John, Roudot, Alice, Staels, Bart, Hum, Dean W, Megnien, Sophie Jeannin, Hosmane, Suneil, Dam, Noémie, Chaumat, Pierre, Hanf, Rémy, Anstee, Quentin M, Sanyal, Arun J

“…Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the…”
Get more information

Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes by Chávez-Talavera, Oscar, Wargny, Matthieu, Pichelin, Matthieu, Descat, Amandine, Vallez, Emmanuelle, Kouach, Mostafa, Bigot-Corbel, Edith, Joliveau, Marielle, Goossens, Jean-François, Le May, Cédric, Hadjadj, Samy, Hanf, Rémy, Tailleux, Anne, Staels, Bart, Cariou, Bertrand

“…Bile acids (BAs) are signaling molecules controlling lipid and glucose metabolism. Since BA alterations are associated with obesity and insulin resistance,…”
Get full text

Safety issues and prospects for future generations of PPAR modulators by Rubenstrunk, Anne, Hanf, Rémy, Hum, Dean W., Fruchart, Jean-Charles, Staels, Bart

“…Because of their wide range of actions on glucose homeostasis, lipid metabolism and vascular inflammation, peroxisome proliferator-activated receptors (PPARs)…”
Get full text

Mo1591 ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ELAFIBRANOR WITH INDOMETHACIN IN HEALTHY ADULT MALE PARTICIPANTS: AN OPEN-LABEL PHASE I TRIAL by Pedret-Dunn, Anna, Mazain, Sarah, Allan, Richard, Gattolliat, Olivier, Hanf, Rémy

Get full text

Mo1585 ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ELAFIBRANOR WITH WARFARIN IN HEALTHY ADULT MALE PARTICIPANTS: AN OPEN-LABEL PHASE I TRIAL by Pedret-Dunn, Anna, Mazain, Sarah, Allan, Richard, Gattolliat, Olivier, Hanf, Rémy

Get full text

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis by Mózes, Ferenc Emil, Lee, Jenny A, Selvaraj, Emmanuel Anandraj, Jayaswal, Arjun Narayan Ajmer, Trauner, Michael, Boursier, Jerome, Fournier, Céline, Staufer, Katharina, Stauber, Rudolf E, Bugianesi, Elisabetta, Younes, Ramy, Gaia, Silvia, Lupșor-Platon, Monica, Petta, Salvatore, Shima, Toshihide, Okanoue, Takeshi, Mahadeva, Sanjiv, Chan, Wah-Kheong, Eddowes, Peter J, Hirschfield, Gideon M, Newsome, Philip Noel, Wong, Vincent Wai-Sun, de Ledinghen, Victor, Fan, Jiangao, Shen, Feng, Cobbold, Jeremy F, Sumida, Yoshio, Okajima, Akira, Schattenberg, Jörn M, Labenz, Christian, Kim, Won, Lee, Myoung Seok, Wiegand, Johannes, Karlas, Thomas, Yılmaz, Yusuf, Aithal, Guruprasad Padur, Palaniyappan, Naaventhan, Cassinotto, Christophe, Aggarwal, Sandeep, Garg, Harshit, Ooi, Geraldine J, Nakajima, Atsushi, Yoneda, Masato, Ziol, Marianne, Barget, Nathalie, Geier, Andreas, Tuthill, Theresa, Brosnan, M Julia, Anstee, Quentin Mark, Neubauer, Stefan, Harrison, Stephen A, Bossuyt, Patrick M, Pavlides, Michael

“…Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the…”
Get more information

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis by Selvaraj, Emmanuel Anandraj, Jayaswal, Arjun Narayan Ajmer, Zafarmand, Mohammad Hadi, Vali, Yasaman, Lee, Jenny A., Levick, Christina Kim, Young, Liam Arnold Joseph, Palaniyappan, Naaventhan, Liu, Chang-Hai, Aithal, Guruprasad Padur, Romero-Gómez, Manuel, Tuthill, Theresa A., Anstee, Quentin M., Neubauer, Stefan, Harrison, Stephen A., Bossuyt, Patrick M., Pavlides, Michael, Anstee, Quentin, Daly, Ann, Johnson, Katherine, Cockell, Simon, Bedossa, Pierre, Oakley, Fiona, Cordell, Heather, Day, Chris, Wonders, Kristy, Zafarmand, Hadi, Vali, Yasaman, Lee, Jenny, Ratziu, Vlad, Pais, Raluca, Schattenberg, Jörn, Vidal-Puig, Toni, Vacca, Michele, Rodrigues-Cuenca, Sergio, Allison, Mike, Kamzolas, Ioannis, Hyötyläinen, Tuulia, McGlinchey, Aiden, Mato, Jose M., Millet, Oscar, Dufour, Jean-François, Berzigotti, Annalisa, Pavlides, Michael, Harrison, Stephen, Neubauer, Stefan, Cobbold, Jeremy, Mozes, Ferenc, Akhtar, Salma, Banerjee, Rajarshi, Kelly, Matt, Erpicum, Charlotte, Romero-Gómez, Manuel, Gómez-González, Emilio, Ampuero, Javier, Gallego-Durán, Rocío, Fernández, Isabel, Montero-Vallejo, Rocío, Fisker, Mette Juul, Sinisi, Antonia, Musa, Kishwar, Sandt, Estelle, Tonini, Manuela, Rosso, Chiara, Armandi, Angelo, Marra, Fabio, Gastaldelli, Amalia, Svegliati, Gianluca, Francque, Sven, Vonghia, Luisa, Luukkonen, Panu, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Petta, Salvatore, Miele, Luca, Geier, Andreas, Aithal, Guru, Wenn, David, Pereira Rodrigues, Cecília Maria, Chaumat, Pierre, Ortiz, Pablo, Duffin, Kevin, Brosnan, Julia, Tuthill, Theresa, Ertle, Judith, Younes, Ramy, Ostroff, Rachel, Alexander, Leigh, Mikkelsen, Lars Friis, Balp, Maria-Magdalena, Jennings, Lori, Loeffler, Juergen, Hanauer, Guido, Fournier, Céline, Pepin, Kay, Ehman, Richard, Myers, Joel, Torstenson, Richard, Doward, Lynda

“…Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance…”
Get full text

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects by Hanf, Rémy, Millatt, Lesley J, Cariou, Bertrand, Noel, Benoit, Rigou, Géraldine, Delataille, Philippe, Daix, Valérie, Hum, Dean W, Staels, Bart

“…We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta (PPARα/δ) agonist, in the db/db…”
Get more information

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production by Colin, Sophie, Briand, Olivier, Touche, Véronique, Wouters, Kristiaan, Baron, Morgane, Pattou, François, Hanf, Rémy, Tailleux, Anne, Chinetti, Giulia, Staels, Bart, Lestavel, Sophie

“…Peroxisome proliferator-activated receptor (PPAR)-α is a transcription factor controlling lipid metabolism in liver, heart, muscle, and macrophages. Peroxisome…”
Get full text

278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis by STAELS, BART, RATZIU, VLAD, SANYAL, ARUN J., FRANCQUE, SVEN, HARRISON, STEPHEN A., ROUDOT, ALICE, BROZEK, JOHN, HAJJI, YACINE, MEGNIEN, SOPHIE, HUM, DEAN W., BIRMAN, PASCAL, HANF, RéMY, CARIOU, BERTRAND

“…Background and Aim: T2D increases the prevalence of steatosis and steatohepatitis (NASH). The aim was to assess the relationship between T2D and two…”
Get full text

279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients by STAELS, BART, RATZIU, VLAD, FRANCQUE, SVEN, HARRISON, STEPHEN A., BEDOSSA, PIERRE, ROUDOT, ALICE, MAJD, ZOUHER, BROZEK, JOHN, BEN-SUDRIK, FOUAD, BIRMAN, PASCAL, HUM, DEAN W., HOSMANE, SUNEIL, CHAUMAT, PIERRE, HANF, RéMY, CARIOU, BERTRAND, SANYAL, ARUN

“…Background and Aim: T2D is an independent risk factor for the development of nonalcoholic steatohepatitis (NASH). Amongst NASH patients, those with elevated…”
Get full text

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance by Johnson, Katherine, Leary, Peter J., Govaere, Olivier, Barter, Matthew J., Cockell, Simon J., Zatorska, Michalina, Bedossa, Pierre, Brosnan, M. Julia, Cobbold, Jeremy F., Ekstedt, Mattias, Aithal, Guruprasad P., Clément, Karine, Schattenberg, Jörn M., Boursier, Jerome, Ratziu, Vlad, Anstee, Quentin M., Daly, Ann K., Clark, James, Cordell, Heather J., Darlay, Rebecca, Day, Christopher P., Hardy, Tim, Liu, Yang-Lin, Oakley, Fiona, Palmer, Jeremy, Queen, Rachel, Bossuyt, Patrick M., Holleboom, Adriaan G., Lee, Jenny, Clement, Karine, Pais, Raluca, Schuppan, Detlef, Allison, Michael, Cuenca, Sergio Rodriguez, Pellegrinelli, Vanessa, Vacca, Michele, McGlinchey, Aidan, Sen, Partho, Mato, Jose, Dufour, Jean-Francois, Neubauer, Stefan, Mozes, Ferenc, Banerjee, Rajarshi, Kelly, Matt, Shumbayawonda, Elizabeth, Dennis, Andrea, Erpicum, Charlotte, Romero-Gomez, Manuel, Gallego-Durán, Rocío, Fernández, Isabel, Karsdal, Morten, Fisker, Mette Juul, Erhardtsen, Elisabeth, Qvist, Per, Tonini, Maria Manuela, Parola, Maurizio, Marra, Fabio, Gastaldelli, Amalia, Francque, Sven, Kechagias, Stergios, Yki-Järvinen, Hannele, Porthan, Kimmo, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Valenti, Luca, Petta, Salvatore, Geier, Andreas, Trautwein, Christian, Hockings, Paul, Newsome, Phil, Chaumat, Pierre, Rosenquist, Christian, Trylesinski, Aldo, Duffin, Kevin, Yunis, Carla, Miller, Melissa, Tuthill, Theresa, Ertle, Judith, Younes, Ramy, Ostroff, Rachel, Mikkelsen, Lars Friis, Brass, Clifford, Jennings, Lori, Balp, Maria-Magdalena, Martic, Miljen, Hanauer, Guido, Shankar, Sudha, Torstenson, Richard, Fournier, Céline, Ehman, Richard, Kalutkiewicz, Michael, Pepin, Kay, Myers, Joel, Shevell, Diane, Ho, Gideon, Landgren, Henrik, Doward, Lynda, Whalley, Diane, Twiss, James

“…Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile…”
Get full text

The cyclo‐oxygenase‐dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2‐mediated relaxation by Rouaud, Céline, Delaforge, Marcel, Anger‐Leroy, Marielle, Le Filliatre, Gaël, Finet, Michel, Hanf, Rémy

“…Arachidonic acid (0.01–1μM) induced relaxation of precontracted rings of rabbit saphenous vein, which was counteracted by contraction at concentrations higher…”
Get full text

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology by Staels, Bart, Rubenstrunk, Anne, Noel, Benoit, Rigou, Géraldine, Delataille, Philippe, Millatt, Lesley J., Baron, Morgane, Lucas, Anthony, Tailleux, Anne, Hum, Dean W., Ratziu, Vlad, Cariou, Bertrand, Hanf, Rémy

Get full text

Dual Peroxisome Proliferator-Activated Receptor [alpha]/[delta] Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects by Cariou, Bertrand, Hanf, Rémy, Lambert-Porcheron, Stéphanie, Zaïr, Yassine, Sauvinet, Valérie, Noël, Benoit, Flet, Laurent, Vidal, Hubert, Staels, Bart, Laville, Martine

“…The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome…”
Get full text

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production by Colin, Sophie, Briand, Olivier, Touche, Véronique, Wouters, Kristiaan, Baron, Morgane, Pattou, François, Hanf, Rémy, Tailleux, Anne, Chinetti, Giulia, Staels, Bart, Lestavel, Sophie

Get full text

THU-174 Assessment of the pharmacokinetic drug-drug interaction potential of elafibranor with atorvastatin in healthy adult male participants: an open-label phase I trial by Pedret-Dunn, Anna, Mazain, Sarah, Allan, Richard, Hanf, Remy, Addy, Carol

Get full text

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis by Vali, Yasaman, Lee, Jenny, Boursier, Jérôme, Spijker, René, Löffler, Jürgen, Verheij, Joanne, Brosnan, M. Julia, Böcskei, Zsolt, Anstee, Quentin M., Bossuyt, Patrick M., Zafarmand, Mohammad Hadi, Pavlides, Michael, Levick, Christina, Duffin, Kevin, Hyde, Craig, Bauer, Tim, Bedossa, Pierre, Leeming, Diana, Daly, Ann, Hanf, Remy, Ortiz, Pablo, Oresic, Matej, Schuppan, Detlef, Hanauer, Guido, Chen, Yu, Shumbayawonda, Elizabeth, Bjerring, Peter Nissen, Zwinderman, Koos

“…The enhanced liver fibrosis (ELF) test has been proposed for the non-invasive assessment of advanced fibrosis in patients with non-alcoholic fatty liver…”
Get full text